Pharma Mar S.A. (MC:PHM) — Stock Price
Pharma Mar S.A. (MC:PHM) is currently trading at €80.90 EUR, up 3.19% today. Over the past 52 weeks, shares have ranged between €67.00 and €103.60. This page tracks Pharma Mar S.A.'s live share price on the MC exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see how much is Pharma Mar S.A. worth.
Pharma Mar S.A. (PHM) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Pharma Mar S.A.'s daily closing share price and trading volume on the MC exchange over the past year, giving a clear view of recent price momentum and liquidity.
Pharma Mar S.A. Income Statement — Revenue, Profit & Earnings by Year
Pharma Mar S.A.'s annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €221.39 Million | €174.85 Million | €158.15 Million | €196.34 Million | €229.83 Million |
| Cost of Revenue | €12.26 Million | €8.18 Million | €9.61 Million | €13.64 Million | €16.44 Million |
| Gross Profit | €209.13 Million | €166.67 Million | €148.54 Million | €182.70 Million | €213.39 Million |
| Research & Development | €95.19 Million | €103.50 Million | €99.30 Million | €83.45 Million | €72.17 Million |
| SG&A | €2.14 Million | €2.85 Million | €18.26 Million | €19.02 Million | €17.37 Million |
| Total Operating Expenses | €168.85 Million | €160.20 Million | €152.37 Million | €138.27 Million | €121.04 Million |
| Operating Income | €40.28 Million | €6.47 Million | €-3.83 Million | €44.07 Million | €92.45 Million |
| EBITDA | €48.30 Million | €21.23 Million | €4.55 Million | €52.07 Million | €104.08 Million |
| EBIT | €40.28 Million | €14.45 Million | €-1.21 Million | €46.17 Million | €98.50 Million |
| Interest Expense | €1.06 Million | €2.47 Million | €2.42 Million | €2.38 Million | €3.37 Million |
| Income Before Tax | €59.65 Million | €11.98 Million | €-3.62 Million | €43.79 Million | €95.13 Million |
| Income Tax Expense | €-15.34 Million | €-14.14 Million | €-4.76 Million | €-5.57 Million | €2.27 Million |
| Net Income | €74.99 Million | €26.12 Million | €1.14 Million | €49.36 Million | €92.86 Million |
Pharma Mar S.A. Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Pharma Mar S.A.'s financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €395.08 Million | €349.64 Million | €340.52 Million | €393.26 Million | €368.39 Million |
| Total Current Assets | €283.42 Million | €250.25 Million | €252.60 Million | €275.18 Million | €295.23 Million |
| Cash & Equivalents | — | — | — | €28.13 Million | — |
| Short-term Investments | €149.41 Million | €91.29 Million | €102.54 Million | €32.61 Million | €88.53 Million |
| Net Receivables | €60.59 Million | €34.68 Million | €27.55 Million | €29.32 Million | €78.91 Million |
| Inventory | €54.10 Million | €50.89 Million | €39.29 Million | €27.75 Million | €10.54 Million |
| Property, Plant & Equipment | — | — | — | €34.72 Million | €26.90 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | €143.25 Million | €141.28 Million | €147.08 Million | €170.30 Million | €190.47 Million |
| Total Current Liabilities | €93.88 Million | €82.69 Million | €95.89 Million | €97.32 Million | €86.35 Million |
| Long-term Debt | €35.55 Million | €39.87 Million | €27.04 Million | €25.88 Million | €33.39 Million |
| Net Debt | €31.60 Million | €-12.16 Million | €-16.36 Million | €-107.18 Million | €-64.02 Million |
| Total Stockholder Equity | €251.83 Million | €208.36 Million | €193.44 Million | €222.96 Million | €177.92 Million |
| Retained Earnings | €233.82 Million | €168.38 Million | €142.22 Million | €156.51 Million | €121.29 Million |
Pharma Mar S.A. Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Pharma Mar S.A. generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €53.13 Million | €6.03 Million | €-13.45 Million | €38.32 Million | €25.68 Million |
| Capital Expenditures | €9.38 Million | €15.51 Million | €15.96 Million | €8.85 Million | €7.80 Million |
| Free Cash Flow | €43.75 Million | €-9.48 Million | €-29.40 Million | €29.47 Million | €17.87 Million |
| Investing Cash Flow | €-60.79 Million | €1.03 Million | €-43.05 Million | €10.88 Million | €18.47 Million |
| Financing Cash Flow | €-36.52 Million | €-5.35 Million | €-32.14 Million | €-13.37 Million | €-27.41 Million |
| Dividends Paid | €13.95 Million | €11.42 Million | €11.69 Million | €11.76 Million | €10.87 Million |
| Stock-Based Compensation | €320.00K | €0.00 | €297.00K | €393.00K | €339.00K |
| Depreciation | €8.02 Million | €6.77 Million | €5.76 Million | €5.90 Million | €5.58 Million |
| Change in Cash | €-45.42 Million | €3.21 Million | €-89.79 Million | €36.47 Million | €17.14 Million |
Pharma Mar S.A. Earnings History — EPS Actual vs. Analyst Estimates
Track Pharma Mar S.A.'s quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Apr 23, 2026 | — | 0.13 | — |
| Mar 05, 2026 | 3.42 | 2.37 | +44.20% |
| Oct 30, 2025 | -0.24 | -0.15 | -56.80% |
| Jul 30, 2025 | 1.33 | 0.03 | +4332.33% |
| Apr 24, 2025 | -0.22 | 0.18 | -222.22% |
| Feb 26, 2025 | 1.06 | -0.14 | +859.36% |
| Oct 29, 2024 | 0.21 | -0.09 | +347.06% |
| Jul 30, 2024 | 0.07 | -0.15 | +146.67% |